CSL Behring Recombinant Facility AG – Trademark Portfolio
Entity Type: 99
CSL Behring Recombinant Facility AG holds 40 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 34 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include AFSTYLA and IDELVION.
Wankdorfstrasse 10
CH-3000 Bern 22
Showing of trademarks Trademarks
Trademark Classifications
CSL Behring Recombinant Facility AG's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does CSL Behring Recombinant Facility AG have?
CSL Behring Recombinant Facility AG has 40 U.S. trademarks filed with the USPTO. Of these, 2 registered, 27 abandoned, 10 cancelled.
What trademark classes does CSL Behring Recombinant Facility AG file in?
CSL Behring Recombinant Facility AG files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CSL Behring Recombinant Facility AG's most well-known trademarks?
CSL Behring Recombinant Facility AG's registered trademark portfolio includes well-known marks such as AFSTYLA and IDELVION. These are among 2 currently registered trademarks in the portfolio.
What is CSL Behring Recombinant Facility AG's trademark registration success rate?
CSL Behring Recombinant Facility AG has a 5% trademark registration rate, with 2 out of 39 resolved applications resulting in successful registration. Currently, 0 applications are pending review.